Sparks commentary

Healthcare

Sparks

FDA approves Vertex’s (NASDAQ: VRTX) pain drug
Published by Arron Aatkar, PhD

The US FDA has approved Vertex’s suzetrigine, now called Journavx, for the treatment of adults with moderate-to-severe acute pain. Vertex has spent many decades in the challenging field of pain management and the approval of  Journavx represents a significant milestone in public health, especially following the opioid epidemic in the US.

 

Latest

Healthcare | Comment

Cantargia (OMX: CANTA) breast cancer study fully recruited

Industrials | Comment

NWF (LON: NWF) acquires Northern Energy Oil

Healthcare | Comment

Cantargia (OMX: CANTA) reports positive CAN10 update

Healthcare | Comment

Oryzon (BME: ORY) publishes results of vafidemstat in PMS

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free